| کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
|---|---|---|---|---|
| 3136489 | 1584972 | 2015 | 6 صفحه PDF | دانلود رایگان |
BackgroundThis is a review of the management considerations regarding exodontia for patients taking antithrombotic medications that affect platelet function or aggregation.MethodsThe authors reviewed the literature, focusing on the indications and mechanisms of antiplatelet therapy and the perioperative management of patients taking these agents who require exodontia or other dentoalveolar surgery.ResultsDentists making management decisions regarding patients taking antiplatelet therapy should consider the patient’s risk of experiencing perioperative hemorrhage against the risk of experiencing complications associated with thromboembolic events. The risk of perioperative bleeding complications is low for patients taking single or dual antiplatelet therapy. Intraoperative and postoperative bleeding can be controlled with local hemostatic measures.ConclusionFor patients taking antiplatelet medication, bleeding risk for exodontia is generally lower than the risk of experiencing thromboembolic events owing to cessation of therapy.Practical ImplicationsDentists can safely complete exodontia in patients who continue taking antiplatelet therapy. The dentist should consult the patient’s prescribing physician before considering altering the patient’s antiplatelet therapy regimen.
Journal: The Journal of the American Dental Association - Volume 146, Issue 11, November 2015, Pages 851–856